Li Wei, Xu Jianxin, Guo Xin, Xia Xinhua, Sun Yanling
Third Medical Department, Tianjin Teda Hospital, Tianjin 300457, P.R. China.
Nursing Department, Tianjin Teda Hospital, Tianjin 300457, P.R. China.
Exp Ther Med. 2021 Apr;21(4):331. doi: 10.3892/etm.2021.9762. Epub 2021 Feb 8.
Diabetes mellitus accelerates the hyperglycemia susceptibility-induced injury to cardiac cells. The activation of peroxisome proliferator-activated receptor α (PPARα) decreases ischemia-reperfusion (IR) injury in animals without diabetes. Therefore, the present study hypothesized that pemafibrate may exert a protective effect on the myocardium and . A type 1 diabetes mellitus (T1DM) rat model and H9c2 cells exposed to high glucose under hypoxia and reoxygenation treatments were used in the present study. The rat model and the cells were subsequently treated with pemafibrate. In the T1DM rat model, pemafibrate enhanced the expression of PPARα in the diabetic-myocardial ischemia-reperfusion injury (D-IRI) group compared with the D-IRI group. The infarct size in the D-IRI group was reduced following pemafibrate treatment relative to the untreated group. The disruption of the mitochondrial structure and myofibrils in the D-IRI group was partially recovered by pemafibrate. In addition, to evaluate the mechanism of action of pemafibrate in the treatment of diabetic myocardial IR injury, an model was established. PPARα protein expression levels were reduced in the high glucose and hypoxia/reoxygenation (H/R) groups compared with that in the control or high glucose-treated groups. Pemafibrate treatment significantly enhanced the ATP and superoxide dismutase levels, and reduced the mitochondrial reactive oxygen species and malondialdehyde levels compared with the high glucose combined with H/R group. Furthermore, pemafibrate inhibited the expression of cytochrome and cleaved-caspase-3, indicating its involvement in the regulation of mitochondrial apoptosis. Pemafibrate also reduced the expression of nuclear factor-κB (NF-κB), the activation of which reversed the protective effects of pemafibrate on diabetic myocardial IR injury . Taken together, these results suggested that pemafibrate may activate PPARα to protect the T1DM rat myocardium against IR injury through inhibition of NF-κB signaling.
糖尿病会加速高血糖易感性诱导的心肌细胞损伤。过氧化物酶体增殖物激活受体α(PPARα)的激活可减轻非糖尿病动物的缺血再灌注(IR)损伤。因此,本研究假设匹伐贝特可能对心肌发挥保护作用。本研究使用了1型糖尿病(T1DM)大鼠模型以及在缺氧和复氧处理下暴露于高糖环境的H9c2细胞。随后,对大鼠模型和细胞进行匹伐贝特处理。在T1DM大鼠模型中,与糖尿病性心肌缺血再灌注损伤(D-IRI)组相比,匹伐贝特增强了D-IRI组中PPARα的表达。与未处理组相比,匹伐贝特处理后D-IRI组的梗死面积减小。匹伐贝特部分恢复了D-IRI组中线粒体结构和肌原纤维的破坏。此外,为了评估匹伐贝特治疗糖尿病性心肌IR损伤的作用机制,建立了一个模型。与对照组或高糖处理组相比,高糖和缺氧/复氧(H/R)组中PPARα蛋白表达水平降低。与高糖联合H/R组相比,匹伐贝特处理显著提高了ATP和超氧化物歧化酶水平,并降低了线粒体活性氧和丙二醛水平。此外,匹伐贝特抑制了细胞色素和裂解的半胱天冬酶-3的表达,表明其参与了线粒体凋亡的调节。匹伐贝特还降低了核因子-κB(NF-κB)的表达,NF-κB的激活逆转了匹伐贝特对糖尿病性心肌IR损伤的保护作用。综上所述,这些结果表明匹伐贝特可能通过抑制NF-κB信号通路激活PPARα来保护T1DM大鼠心肌免受IR损伤。